US-based AcuFocus has submitted the KAMRA intra-corneal inlay’s final premarket approval application (PMA) module to the US Food and Drug Administration (FDA).

KAMRA is an opaque circular micro-disc with a small opening (1.6mm) in the centre and, when placed in the cornea, blocks unfocused light, only allowing focused light to reach the retina.

“KAMRA is an opaque circular micro-disc with a small opening (1.6mm) in the centre and, when placed in the cornea, blocks unfocused light, only allowing focused light to reach the retina.”

The device helps patients to regain the reading vision they had prior to presbyopia, and allows them to perform daily activities such as reading text messages, checking the time on a wristwatch and reading store shelf prices without glasses.

US clinical trials investigator John Vukich said; “Patients, practitioners and the ophthalmic industry have all been in search of a reliable corneal solution for presbyopia and I believe the KAMRA inlay is that solution.”

AcuFocus CEO and president Ed Peterson said; “After 10 years of development and thousands of patients treated globally, it is incredible to finally be able to submit this last module to the FDA for US approval.”

AcuFocus chief clinical officer Corina van de Pol said KAMRA is the first corneal inlay for treatment of presbyopia submitted for US approval.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We look forward to working with the FDA throughout the review process,” van de Pol said.

The device is currently available for sale in 47 nations around the world.